Business Description
Jasper Therapeutics Inc
NAICS : 325412
SIC : 2834
2200 Bridge Parkway, Suite No. 102, Redwood, CA, USA, 94065
Description
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 15.14 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.09 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | 0 | |||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48.82 | |||||
| 9-Day RSI | 51.12 | |||||
| 14-Day RSI | 49.82 | |||||
| 6-1 Month Momentum % | -60.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.56 | |||||
| Quick Ratio | 9.56 | |||||
| Cash Ratio | 9.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -36.48 | |||||
| ROA % | -28.52 | |||||
| ROIC % | -574.64 | |||||
| ROC (Joel Greenblatt) % | -822.73 | |||||
| ROCE % | -53.91 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.2 | |||||
| Price-to-Tangible-Book | 1.37 | |||||
| EV-to-EBIT | -0.39 | |||||
| EV-to-Forward-EBIT | -0.36 | |||||
| EV-to-EBITDA | -0.39 | |||||
| EV-to-Forward-EBITDA | -0.36 | |||||
| EV-to-FCF | -0.23 | |||||
| Price-to-Net-Current-Asset-Value | 1.57 | |||||
| Price-to-Net-Cash | 1.64 | |||||
| Earnings Yield (Greenblatt) % | -253.26 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:JSPR
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -1.279 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 49.82 | ||
| 14-Day ATR ($) | 0.221346 | ||
| 20-Day SMA ($) | 2.06325 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 1.73 - 18.88 | ||
| Shares Outstanding (Mil) | 36.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Jasper Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||